Baseline lung function and bronchial hyperresponsiveness, area under curves for dose-response to salbutamol, and post-salbutamol bronchial hyperresponsiveness after each treatment period. Results reported as mean (95% confidence interval). PD20: Provocative dose causing a ≥20% in forced expired volume in one second (FEV1)
| Placebo | Formoterol | Formoterol plus hydrocortisone | |
| Subjects n | 10 | 10 | 9 |
| Baseline FEV1 L | 2.59 (2.16–3.02) | 2.59 (2.14–3.04) | 2.45 (2.02–2.88) |
| PD20 for first methacholine challenge μmol | 2.12 (0.57–3.67) | 1.57 (0.34–2.80) | 3.43 (0.31–6.55) |
| FEV1 fall from baseline % | 25.91 (22.44–29.38) | 25.81 (21.99–29.63) | 25.35 (22.51–28.19) |
| AUC0–15 | 7.72 (6.84–8.60) | 5.49 (4.61–6.37) | 5.56 (4.09–7.05) |
| AUC0–45 | 35.36 (30.03–40.68) | 24.94 (19.62–30.26) | 27.06 (20.38–33.75) |
| FEV1 before second methacholine challenge | 2.97 (2.81–3.13) | 2.84 (2.68–3.00) | 2.84 (2.57–3.11) |
| PD20 for methacholine challenge after salbutamol μmol | 23.19 (8.94–37.44) | 12.12 (2.89–21.35) | 19.30 (2.31–36.29) |